⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15369942 | 1.00 | — | — | |
| SCHEMBL1064821 | 1.00 | — | — | |
| SCHEMBL10044382 | 0.97 | EPHX2 (0.68) | — | |
| SCHEMBL12476306 | 0.97 | EPHX2 (0.76) | — | |
| SCHEMBL5243600 | 0.97 | EPHX2 (0.68) | — | |
| SCHEMBL17691129 | 0.97 | EPHX2 (0.76) | — | |
| SCHEMBL10041880 | 0.97 | EPHX2 (0.76) | — | |
| SCHEMBL28619137 | 0.97 | EPHX2 (0.68) | — | |
| SCHEMBL12442307 | 0.87 | EPHX2 (0.58) | — | |
| SCHEMBL13921587 | 0.87 | EPHX2 (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-8962843-B2 | 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors | CUBIST PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962844-B2 | 1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors | CUBIST PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20150038482-A1 | ISOXAZOLE BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2015-02-05 | — | — | US | disclosed |
| US-20150038479-A1 | ISOXAZOLE BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2015-02-05 | — | — | US | disclosed |
| US-20150031659-A1 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2015-01-29 | — | — | US | disclosed |
| US-20150031665-A1 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2015-01-29 | — | — | US | disclosed |
| US-8940897-B2 | 1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors | CUBIST PHARMACEUTICALS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8933232-B2 | 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors | CUBIST PHARMACEUTICALS, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20130296291-A1 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-11-07 | — | — | US | disclosed |
| US-20130023514-A1 | SUBSTITUTED PYRROLOTRIAZINES AS PROTEIN KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-24 | — | — | US | disclosed |
| EP-1954668-B9 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-1954668-B1 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-09-28 | — | — | EP | disclosed |
| WO-2011064211-A1 | BENZENE-FUSED 6-MEMBERED OXYGEN-CONTAINING HETEROCYCLIC DERIVATIVES OF BICYCLIC HETEROARYLS | NOVARTIS AG (CH) | 2011-06-03 | — | — | WO | disclosed |
| US-7888376-B2 | Cholesteryl ester transfer protein (CETP) inhibitors; atherosclerosis and cardiovascular diseases; N-(1-(5-chloropyridin-2-yl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-4-(trifluoromethyl)thiazol-2-amine; Alzheimer's, atherosclerosis, venous thrombosis, peripheral vascular disease | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-15 | — | — | US | disclosed |
| US-20100267669-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-7790770-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| WO-2007062314-A2 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |